Debevoise Advises Johnson & Johnson in Its Acquisition of Novel Drug Delivery Technology for Treatment of Cancer

23 December 2019

Debevoise & Plimpton LLP is advising Johnson & Johnson (NYSE: JNJ) in its acquisition of TARIS Biomedical LLC (TARIS), a privately owned biotechnology company specializing in the development of a novel drug delivery technology for the treatment of bladder diseases, including cancer. The company’s lead product, TAR-200, uses the proprietary TARIS System, which features a silicone-based drug delivery device that allows for the continuous release of medication into the bladder. It is deployed and retrieved using minimally invasive, in-office procedures. This technology allows drug release to be tailored to match the needs of each disease. For more information, please see Johnson & Johnson’s press release.

Johnson & Johnson, the world’s largest and most broadly based healthcare company, with a market capitalization of approximately $380 billion, develops medical devices, pharmaceutical and consumer packaged goods.

The Debevoise team is led by M&A partners Kevin Rinker and Jennifer Chu and includes associates Alexandra Grossman, David Iozzi and Chibundu Ifeoma Okwuosa, tax partner Peter Furci and associate Samuel Krawiecz, benefits partner Meir Katz and associate Jeri Brown, intellectual property partner Jeffrey Cunard and associate Benjamin Sundholm, and FDA regulatory partner Paul Rubin and associate Melissa Runsten.